Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program
NEW YORK, April 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0832795/Pricing-and-Reimbursement-in-Russia---Big-Pharma-Take-Advantage-of-Reimbursement-for-Costly-Drugs-Through-the-DLO's-Seven-Nosologies-Program.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program". It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law "On Circulation of Drugs".
The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centers was done. The launch of the DLO (the acronym for Additional Medicines Supply Program) program was done for disabled persons, pensioners and patients in need of specialized medicines. It was estimated by the Ministry of Health and Social Development that 15 million people will be covered under this program. Since the option of opting for money instead of medicine was provided under the program, a greater number of patients opted for the money. Those patients who opted for medicines got a chance to be treated by some of the best medicines available for their respective therapy areas.
The VZN program (acronym for Seven Nosologies Program) was segmented from the DLO. This was because there is a set of people who need specialized medicines which are particularly expensive. The other segment of the DLO program is called the Essential Drug Program (ONLS). Compulsory medical insurance for all Russians was introduced in 1995. Under the medical insurance plan Russians recieve treatment, hospitalization, surgical operation, dental care and other facilities free of charge. However, state medical insurance does not seem to be sufficient for all Russians, so private insurance (voluntary medical insurance) players are also active in the field. The implementation of the new law "on circulation of drugs" resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia. This means that the Russian government will now regulate the prices of drugs more uniformly. The decision of the Russian government to boost the domestic pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Many major global pharmaceutical companies are initiating and expanding their production capacities in Russia to penetrate further into this market.
Scope
- Detailed study of the healthcare scenario in the Russia.
- Analysis of the pricing and reimbursement mechanisms in Russia.
- Key changes that follow from the implementation of new law "on circulation of drugs" in the pricing and reimbursement system.
- Details about government bodies which regulate different processes of pricing and reimbursement in Russia.
- Details about share of major companies in reimbursement program of Russia.
- Insight into various reimbursement programs in Russia.
Reasons to buy
- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Russia.
- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Russia.
- Knowledge about the regulatory bodies who undertake different processes of price registration.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Russia.
- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 5
2 Pricing and Reimbursement in Russia - Introduction 7
2.1 GBI Research Report Guidance 7
3 Pricing and Reimbursement in Russia - Overview 8
3.1 Introduction to Healthcare System in Russia 8
3.1.1 Comparative Analysis 8
4 Pricing and Reimbursement in Russia - Overview of Pharmaceutical Market in Russia 14
4.1 Healthcare System in Russia 14
4.1.1 Health Indicators in Russia 14
4.1.2 Private Expenditure on Health 18
4.1.3 Segmentation of Russian Pharmaceutical Market 20
4.2 PEST Analysis of Russian Pharmaceutical Market 21
4.2.1 Political 21
4.2.2 Economical 21
4.2.3 Social 21
4.2.4 Technological 22
4.3 Drug Expenditure 22
4.3.1 Drug Expenditure as Percentage of Healthcare Expenditure 22
4.4 Russian Pharmaceutical Market Segmented by Therapeutic Area 23
5 Pricing and Reimbursement in Russia - Drug Pricing in Russia 25
5.1 Introduction 25
5.1.1 Drug Price Authorities in Russia 25
5.1.2 Price Registration in Russia 26
5.2 Price Setting Procedures 29
5.2.1 Essential Drugs List (EDL) Pricing 29
5.2.2 Historical Pricing Procedures 30
5.2.3 Current Pricing Procedures 30
5.2.4 Reasons to Change Prevailing Pricing Procedures 31
5.3 Type of Compensation for EDL Drugs 31
5.4 Share of Domestic Drugs in EDL 32
5.4.1 Share of Domestic Drugs in EDL by Sales Value 32
5.4.2 Share of Domestic Drugs in EDL by Sales Volume 33
5.5 Share of EDL in Russian Pharmaceutical Market 34
5.5.1 Share of EDL in Russian Pharmaceutical Market by Sales Value 34
5.5.2 Share of EDL Drugs in Russian Pharmaceutical Market by Sales Volume 35
6 Pricing and Reimbursement in Russia - Reimbursement Programs in Russia 36
6.1 Introduction 36
6.1.1 DLO - Reimbursement Program of Russia 36
6.1.2 The Seven Nosologies Program (VZN) 44
6.1.3 ONLS Program 49
6.2 Insurance System 50
7 Pricing and Reimbursement in Russia - Appendix 51
7.1 Market Definitions 51
7.2 Abbreviations 51
7.3 Research Methodology 52
7.3.1 Healthcare System 52
7.3.2 Pharmaceutical Regulations 52
7.3.3 Pricing of Pharmaceutical Drugs 52
7.3.4 Reimbursement of Pharmaceutical Drugs 53
7.3.5 Pricing and Reimbursement in Major Therapy Areas 53
7.4 Contact Us 53
7.5 Disclaimer 53
7.6 Sources 53
1.1 List of Tables
Table 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006-2009 9
Table 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a percentage of GDP, BRIC vs The US, 2010-2050 10
Table 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006-2009 11
Table 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006-2009 12
Table 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006-2009 13
Table 6: Pricing and Reimbursement in Russia, Health Indicators, Russia, 2009 14
Table 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010 15
Table 8: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010 15
Table 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010 16
Table 10: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010 17
Table 11: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000-2009 18
Table 12: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000-2009 19
Table 13: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009-2010 20
Table 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009-2010 22
Table 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009-2010 23
Table 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009-2010 24
Table 17: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009-2010 32
Table 18: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009-2010 33
Table 19: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009-2010 34
Table 20: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009-2010 35
Table 21: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005-2010 36
Table 22: Pricing and Reimbursement in Russia, Total Value of DLO Program, Russia, 2007-2010 37
Table 23: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009-2010 38
Table 24: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008-2009 39
Table 25: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009-2010 40
Table 26: Pricing and Reimbursement in Russia, Top 15 Companies in DLO Sector, Sales Value, %, Russia, 2008-2010 41
Table 27: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009-2010 42
Table 28: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009-2010 43
Table 29: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, (%), 2008-2009 45
Table 30: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009-2010 46
Table 31: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, Russia, 2008-2009 47
Table 32: Pricing and Reimbursement in Russia, Segmentation of Drugs in VZN Program by Price Range, Sales Value, %, 2009-2010 48
Table 33: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in ONLS Program, Sales Value, %, Russia, 2009-2010 49
Table 34: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000-2009 50
1.2 List of Figures
Figure 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006–2009 8
Figure 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a Percentage of GDP, BRIC vs The US, 2010–2050 10
Figure 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006–2009 11
Figure 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006–2009 12
Figure 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006–2009 13
Figure 6: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010 14
Figure 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010 15
Figure 8: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010 16
Figure 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010 17
Figure 10: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000–2009 18
Figure 11: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000–2009 19
Figure 12: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009–2010 20
Figure 13: Pricing and Reimbursement in Russia, PEST Analysis of Russian Pharmaceutical Market, 2011 21
Figure 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009–2010 22
Figure 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009–2010 23
Figure 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009–2010 24
Figure 17: Pricing and Reimbursement in Russia, Steps for Entering Pricing and Reimbursement, Russia, 2009 26
Figure 18: Pricing and Reimbursement in Russia, Steps for EDL Formation, Russia, 2009 27
Figure 19: Pricing and Reimbursement in Russia, Steps for Price Registration, Russia, 2009 27
Figure 20: Pricing and Reimbursement in Russia, Registration of Maximum Selling Price of Foreign - Manufactured Drugs, Currency of Price Registration, Russia, 2011 28
Figure 21: Pricing and Reimbursement in Russia, Types of Compensation for EDL Drugs, Russia, 2011 31
Figure 22: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009–2010 32
Figure 23: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009–2010 33
Figure 24: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009–2010 34
Figure 25: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009–2010 35
Figure 26: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005–2010 36
Figure 27: Pricing and Reimbursement in Russia, Total Value of DLO Program, $bn, Russia, 2007–2010 37
Figure 28: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009–2010 38
Figure 29: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008–2009 39
Figure 30: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009–2010 40
Figure 31: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009–2010 42
Figure 32: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009–2010 43
Figure 33: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, 2008–2009 44
Figure 34: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009–2010 46
Figure 35: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, Russia, 2008–2009 47
Figure 36: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in VZN Program, Sales Value, %, 2009–2010 48
Figure 37: Pricing and Reimbursement in Russia, Segmentation of Drugs in ONLS Program by Price Range, Sales Value, %, Russia, 2009–2010 49
Figure 38: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000–2009 50
Companies mentioned
To order this report:
Drug and Medication Industry: Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article